 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...2627282930313233343536...4748» |
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2132;
P2
Anlotinib plus sintilimab showed a promising antitumor activity with a favorable toxicity profile for patients with recurrent advanced endometrial cancer. We will report more data in the future.
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2107;
Anlotinib plus sintilimab showed a promising efficacy with a favorable toxicity profile for pts with advanced CC. We will report more data in the future.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, J&J, Takeda
[VIRTUAL] Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer (ANNIE): A multicenter, single-arm, phase II trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2069;
P2
We will report more data in the future. Niraparib in combination with anlotinib showed promising antitumor activity and tolerable toxicity in patients with platinum resistant recurrent ovarian cancer.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
[VIRTUAL] Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): a multicenter, single-arm, open-label, phase Ib trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2068;
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2065;
Niraparib in combination with anlotinib showed promising antitumor activity and tolerable toxicity in patients with platinum resistant recurrent ovarian cancer. The treatment of anlotinib plus pemetrexed showed encouraging efficacy and satisfactory safety for platinum-resistant recurrent ovarian cancer patients who were previously treated with chemotherapy.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib in patients with recurrent platinum-resistant or -refractory ovarian carcinoma: A prospective, single-arm, single-center, phase II clinical study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_2063;
The treatment of anlotinib plus pemetrexed showed encouraging efficacy and satisfactory safety for platinum-resistant recurrent ovarian cancer patients who were previously treated with chemotherapy. Anlotinib showed a promising efficacy with an acceptable safety profile for patients with recurrent platinum-resistant or -refractory ovarian carcinoma.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Update results from ALTER-C-001 study: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC: A single arm, multi-center, phase II clinical trial () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1787;
The update suggested that anlotinib combined with XELOX as first line regimen followed by anlotinib monotherapy showed a promising clinical benefit and favorable safety profile for mCRC. And the needed to be confirmed in trials continued subsequently.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002) () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1783;
P2
Anlotinib combined with CAPEOX achieved higher ORR in the first-line treatment of mCRC compared to those of previous treatment. Longer follow-up is needed for more complete assessment, and we’re launching a phase III, multicenter, double-blind trial to further assess the efficacy of this regimen.
- Avastin (bevacizumab) / Roche, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus temozolomide for recurrent glioma: A single-center, retrospective study of 30 cases () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1732;
Anlotinib combined with TMZ was effective in terms of PFS, ORR, and DCR, and was well tolerated. Further randomized controlled clinical studies are needed to confirm the efficacy of Anlotinib combined with TMZ for the treatment of rMG.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] A phase II study of anlotinib in the treatment of recurrent high-grade glioma () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1731;
P2
Eligible patients were aged more than 18 years old, histologically confirmed high grade glioma with progression after surgery followed by radiotherapy and temozolomide chemotherapy. This interim analysis showed anlotinib is effective and well toleranced for recurrent high-grade glioma patients.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, Zejula (niraparib) / GSK, J&J, Takeda
[VIRTUAL] A phase I trial of niraparib plus anlotinib in advanced solid tumors with homologous recombination repair (HRR) gene mutations () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1716;
P1
In the second stage, 40 patients will be included to treated with Niraparib plus Anlotinib every 21 days using the MTD determined by the first stage, until disease progression or intolerable toxicity or withdrawal of the trial. Currently, 1 of the planned 52 patients have been enrolled; enrollment is ongoing.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1560;
Chemotherapy comprised epirubicin at 90 mg/m2 and cyclophosphamide at 600 mg/m2 followed by docetaxel at 100 mg/m2, (21 days per cycle; both total 4 cycles), which was then followed by surgery. The addition of anlotinib to neoadjuvant chemotherapy showed manageable toxicity and promising antitumor activity for patients with high-risk, early-stage TNBC.
- | Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy, Metastases: Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (clinicaltrials.gov) - Jul 21, 2021
P2, N=32, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Bosulif (bosutinib) / Pfizer, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Quinoline-based compounds with potential activity against drug-resistant cancers. (Pubmed Central) - Jul 21, 2021
The present short review article provides an overview about the recent advances of quinoline-based compounds with potential activity against drug-resistant cancers. The structure-activity relationship and mechanisms of action are also discussed.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, Rydapt (midostaurin) / Novartis
Preclinical, Journal: Indole alkaloids, synthetic dimers and hybrids with potential in vivo anticancer activity. (Pubmed Central) - Jul 21, 2021
Vinblastine, midostaurin, and anlotinib as the representative of indole alkaloids, synthetic dimers and hybrids respectively have already been clinically applied to treat many types of cancers, demonstrating indole alkaloids, synthetic dimers and hybrids are useful scaffolds for the development of novel anticancer agents. Covering articles published between 2010 and 2020, this review emphasizes the recent development of indole alkaloids, synthetic dimers and hybrids with potential in vivo therapeutic application for cancers.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Metastases: Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Jul 21, 2021
P2, N=100, Recruiting, Sponsor: Chinese Academy of Medical Sciences
Covering articles published between 2010 and 2020, this review emphasizes the recent development of indole alkaloids, synthetic dimers and hybrids with potential in vivo therapeutic application for cancers. Not yet recruiting --> Recruiting
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Real-world evidence, Real-world, Metastases: Anlotinib for Esophageal Cancer (AFEC) (clinicaltrials.gov) - Jul 18, 2021
P, N=200, Recruiting, Sponsor: Anyang Tumor Hospital
- | Mekinist (trametinib) / Novartis, BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1 trial, Metastases: Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients (clinicaltrials.gov) - Jul 18, 2021
P1, N=30, Not yet recruiting, Sponsor: Shanghai Chest Hospital
- | Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: ZJCH-SCLC-01: A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLC (clinicaltrials.gov) - Jul 18, 2021
P2, N=23, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P2 data, Journal: Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. (Pubmed Central) - Jul 18, 2021
P2
The use of anlotinib in previously treated, recurrent, or metastatic ESCC patients significantly improved PFS compared with placebo. Our findings suggest that antiangiogenesis might be an important therapeutic target in advanced ESCC.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Construction and antitumor effects of antitumor micelles with cyclic RGD-modified anlotinib. (Pubmed Central) - Jul 17, 2021
In a B16F10 tumor-bearing mouse model, cRGDyk-anlotinib-RM (cARM) showed better tumor tissue accumulation and internalization than those for non-reduction-sensitive micelles. Therefore, this reduction-sensitive drug delivery system benefits from its specificity, prolonged blood circulation time, effective absorption by tumor cells, and rapid release of intracellular drugs and is therefore a promising strategy.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal: The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution. (Pubmed Central) - Jul 17, 2021
Anlotinib was effective against DF with an acceptable safety profile, and significantly slowed the disease progression. Further, multicenter studies with a longer follow-up time are needed to characterize fully the clinical application of anlotinib in DF.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
New P3 trial, Metastases: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) - Jul 15, 2021
P3, N=375, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Tevimbra (tislelizumab) / BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P1/2 trial, Combination therapy, Metastases: TAXE-GC: TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma (clinicaltrials.gov) - Jul 14, 2021
P1/2, N=66, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Monotherapy, Interview: Prof Brian Van Tine @bvantine1 speaks to ecancer about the #APROMISS trial on AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma. Watch the interview here > > https://t.co/Yul0q18wSa #sarcomaawarenessmonth #sarcomaawareness #ASCO21 @WUSTL (Twitter) - Jul 14, 2021
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
P1/2 data, Journal: Anlotinib, Vincristine and Irinotecan (AVI) for Advanced Ewing Sarcoma after Failure of Standard Multimodal Therapy: A Two-cohort, Phase Ib/II Trial. (Pubmed Central) - Jul 14, 2021
Median overall survival was not matured. We demonstrated that the combination of vincristine, irinotecan and anlotinib demonstrated an acceptable toxicity profile and promising clinical efficacy in patients with advanced EWS.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: ALTN-Ⅱ-01: Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Jul 13, 2021
P2, N=150, Recruiting, Sponsor: Sun Yat-sen University
- || Clinical, Journal: Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer. (Pubmed Central) - Jul 11, 2021
The described method to simultaneously quantify the 12 selected anticancer drugs in human plasma was successfully validated and applied to routine TDM of gefitinib, erlotinib, icotinib, osimertinib, crizotinib and anlotinib in cancer patients. TKIs plasma monitoring helps to individualize dose adjustment and manage adverse effects in NSCLC patients.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Real-world evidence, Real-world, Metastases: AFHC: Anlotinib for Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 7, 2021
P, N=200, Recruiting, Sponsor: Guangxi Zhuang Autonomous Region People's Hospital
- || Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy, Metastases: ALTER-T002: Anlotinib or Penpulimab in Combination With RAI for DTC (clinicaltrials.gov) - Jul 7, 2021
P2, N=40, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | Tyvyt (sintilimab) / Eli Lilly, AiTan (rivoceranib) / HLB Bio Group
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: CO-STAR: Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer (clinicaltrials.gov) - Jul 7, 2021
P2, N=50, Recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
TKIs plasma monitoring helps to individualize dose adjustment and manage adverse effects in NSCLC patients. N=30 --> 50 | Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Jun 2022
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases. (Pubmed Central) - Jul 6, 2021
Tumor re-biopsy should be performed routinely when EGFR-TKI therapy fails in lung cancer patients to avoid ignoring histological transformation and to select a subsequent therapeutic strategy. The transformed tumor retained the original EGFR mutation, indicating that histological transformation represents an evolution from the initial tumor.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm
📣It's #SarcomaAwarenessMonth & #BoneCancerAwarenessMonth and we're spotlighting some important updates in these disease areas... APROMISS: catequentinib in synovial #Sarcoma w/ @bvantine1 (@WUSTL) 👉https://t.co/zayHbvZWXB👈 @ASCO #ASCO21 @OncoAlert (Twitter) - Jul 1, 2021
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Adjuvant Therapy With Anlotinib for HCC (clinicaltrials.gov) - Jun 30, 2021
P2, N=0, Withdrawn, Sponsor: Shanghai Zhongshan Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Journal: Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells. (Pubmed Central) - Jun 30, 2021
Meanwhile, we demonstrated that TFAP2A binds to accessible sites within BMP4 and HSPG2. Collectively, this study suggests that TFAP2A accelerates anlotinib resistance by promoting tumor-induced angiogenesis.
- | Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial primary completion date: NeoSACT: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (clinicaltrials.gov) - Jun 30, 2021
P2, N=46, Not yet recruiting, Sponsor: Guangdong Provincial People's Hospital
Collectively, this study suggests that TFAP2A accelerates anlotinib resistance by promoting tumor-induced angiogenesis. Trial primary completion date: May 2022 --> Dec 2022
- | Imfinzi (durvalumab) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Trial initiation date: Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer (clinicaltrials.gov) - Jun 29, 2021
P2, N=120, Not yet recruiting, Sponsor: Henan Cancer Hospital
Trial primary completion date: May 2022 --> Dec 2022 Initiation date: Apr 2021 --> Jul 2021
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial initiation date, Metastases: Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy (clinicaltrials.gov) - Jun 29, 2021
P2, N=30, Recruiting, Sponsor: Junling Li
Initiation date: Apr 2021 --> Jul 2021 Not yet recruiting --> Recruiting | Initiation date: Feb 2021 --> Jun 2021
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Review, Journal: Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety. (Pubmed Central) - Jun 26, 2021
Our study suggested that anlotinib as maintenance therapy for advanced NSCLC patients is associated with prolonged PFS and OS as well as DCR improvement, but it was accompanied by increased risk of TRAE, such as hypertension, hepatic dysfunction, diarrhea and hemoptysis. Although much effort has been made to clinical trials of anlotinib, further studies are warranted to provide more convincing evidence.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation (clinicaltrials.gov) - Jun 23, 2021
P2, N=61, Recruiting, Sponsor: Sun Yat-sen University
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, P3 data, Retrospective data, Journal: The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303). (Pubmed Central) - Jun 22, 2021
P2/3
Its special effect on BM and cerebral tissue merits further investigation. (ClinicalTrials.gov ID: NCT02388919).
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal: Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma. (Pubmed Central) - Jun 22, 2021
P2
This case also underscores the importance of molecular diagnosis for clinically complex cases. Tumor tissue-based assessment of molecular biomarkers in brain tumors has been successfully translated into clinical application.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical data, Retrospective data, Journal: Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study. (Pubmed Central) - Jun 22, 2021
Earlier occurrence of small cell transformation after EGFR-TKI treatment was associated with poorer prognosis of patients. After the standard chemotherapy regimens for the management of primary SCLC, anlotinib may be a therapeutic option.
- || Focus V (anlotinib) / Advenchen, Sino Biopharm
Clinical, Journal, PD(L)-1 Biomarker, IO biomarker: Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib. (Pubmed Central) - Jun 22, 2021
Herein, we reported two PPC patients with different targetable gene mutations who both responded dramatically to the PD-1 inhibitor camrelizumab combined with the oral anti-angiogenic drug anlotinib: one harbouring a BRAF V600E mutation with positive PD-L1 expression, few tumour-infiltrating lymphocytes (TILs) and abundant tumour blood vessels; and the other exhibiting a MET exon 14 skipping mutation with PD-L1 overexpression, scattered TILs and abundant tumour blood vessels. Our findings suggest that PD-1 inhibitor combined with anlotinib may be a potential treatment for PPC patients, and abundant tumour vessels should be investigated as a possible therapeutic biomarker.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Preclinical, Journal: Traditional Chinese Medicine Brucea Javanica Oil Enhances the Efficacy of Anlotinib in a Mouse Model of Liver-Metastasis of Small-cell Lung Cancer. (Pubmed Central) - Jun 22, 2021
Our findings suggest that PD-1 inhibitor combined with anlotinib may be a potential treatment for PPC patients, and abundant tumour vessels should be investigated as a possible therapeutic biomarker. The results of the present study indicate that the combination of anlotinib with BJO is promisingly active against liver metastases of SCLC, and has clinical potential.
- | Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Sintilimab in Treating Advanced Lung Squamous Cell Carcinoma After Fourth-Line Treatment of Anlotinib Resistance. (Pubmed Central) - Jun 22, 2021
The results of the present study indicate that the combination of anlotinib with BJO is promisingly active against liver metastases of SCLC, and has clinical potential. No abstract available
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Combination therapy: STAMP: Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer (clinicaltrials.gov) - Jun 21, 2021
P2, N=50, Not yet recruiting, Sponsor: Liu Zhenhua
- || Zaltrap (ziv-aflibercept IV) / Sanofi, Avastin (bevacizumab) / Roche, Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Angiogenesis Inhibitors in Small Cell Lung Cancer. (Pubmed Central) - Jun 16, 2021
Only anlotinib improved OS and PFS as third-line therapy in Chinese patients with SCLC, and it was approved with this indication in China. Future challenges are the evaluation of the role of angiogenesis inhibitors in combination with immune- checkpoint inhibitors and chemotherapy in SCLC patients and the identification of predictive biomarkers of response to both agents.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
En castellano, por sugerencia de @saezatxa 😜, mis 2 principales notas de #ASCO21 en #CancerdeTiroides🦋 🌶️COSMIC311 (@Ja_Capdevila) Cabozantinib nueva opción tras un TKI previo 🌶️Anlotinib parece funcionar como neoadyuvancia (tumores grandes antes de RAI) Si se puede @aecat_es (Twitter) - Jun 11, 2021
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal, Combination therapy, IO biomarker: Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells. (Pubmed Central) - Jun 11, 2021
Future challenges are the evaluation of the role of angiogenesis inhibitors in combination with immune- checkpoint inhibitors and chemotherapy in SCLC patients and the identification of predictive biomarkers of response to both agents. The combination of anlotinib and DHA showed synergistic antitumor activity, suggesting their potential in treating patients with gastric cancer.